References
- Herrup K, Carrillo MC, Schenk D, et al. Beyond amyloid: getting real about nonamyloid targets in Alzheimer’s disease. Alzheimers Dement 2013;9(4):452-8
- Reitz C. Alzheimer’s disease and the amyloid cascade hypothesis: a critical review. Int J Alzheimers Dis 2012;2012:369808
- Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 2011;10:698-712
- Karren E, Hardy J. Antiamyloid therapy for Alzheimer’s disease – are we on the right road? N Engl J Med 2014;370(4):377-8
- Podlisny MB, Stephenson DT, Frosch MP, et al. Microinjection of synthetic amyloid ß-protein in monkey cerebral cortex fails to produce acute neurotoxicity. Am J Pathol 1993;142:17-24
- Romero K, Corrigan B, Neville J, et al. Striving for an integrated drug development process for neurodegeneration: the coalition against major diseases. Neurodegen Dis Manage 2011;1(5):379-85
- Romero K, de Mars M, Frank D, et al. The Coalition Against Major Diseases: developing tools for an integrated drug development process for Alzheimer’s and Parkinson’s diseases. Clin Pharmacol Ther 2009;86(4):365-7
- Stephenson DT, Aviles E, Bain LJ, et al. Coalition Against Major Diseases: precompetitive collaborations and regulatory paths to accelerating drug development for neurodegenerative diseases. Ther Innov Regul Sci 2013;47:632-8
- Hill DLG, Schwarz AJ, Isaac M, et al. CAMD/EMA biomarker qualification of hippocampal volume for enrichment of clinical trials in pre-dementia stages of Alzheimer’s disease. Alzheimers Dement; In press
- Snyder HM, Bain LJ, Egge R, Carrillo MC. Alzheimer’s disease public-private partnerships: a landscape of the global nonprofit community. Alzheimers Dement 2013;9(4):466-71